Ability of 
68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients. This evidence concerns the gene FOLH1 and prostate cancer.